Various pharmaceutical products for rescEU Medical -project

Finnish Institute for Health and Welfare, later referred to as THL or Customer, request your tender for various pharmaceutical products to the rescEU Medical -project. The Scope of procurement is described in more detail in the Annex 1. The procurement is divided in ten (10) lots. Each Article constitutes a separate lot. Tender may be submitted for one or several lots. LOT 1: Electrolytes (ringer's solution) 1000 ml (intravenous infusion, ATC B05BB01) LOT 2: Electrolytes with carbohydrates 50 mg/ml (500 ml, solution for infusion, ATC B05BB02) LOT 3: Esketamine 25 mg/ml (2 ml, solution for injection/infusion, ATC N01AX14) LOT 4: Oxycodone 10 mg/ml (1 ml, solution for injection, ATC N02AA05) LOT 5: Oxycodone 10 mg/ml (10 ml, solution for injection, ATC N02AA05) LOT 6: Levetiracetam 100 mg/ml (5 ml, concentrate for solution for infusion, ATC N03AX14) LOT 7: Cefuroxime 1500 mg (powder for solution for injection, ATC J01DC02) LOT 8: Vancomycin 1000 mg (powder for solution for injection, ATC J01XA01) LOT 9: Enoxaparin 100 mg/ml (1 ml, sub-cutaneous, ATC B01AB05) LOT 10: Tranexamic acid 100 mg/ml (10 ml, intra muscular/intravenous, ATC B02AA02) The tender shall consist of one (1) Article for each tendered lot. The minimum requirements for the Article is described in the Annex 1.1. The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the Contract has been signed by contracting parties and expires when all contractual duties of the Contract have been performed. Quantity for the Articles is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of December 2028 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. Call for tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract draft Annex 3 Security annex Annex 4 JYSE 2025 SUPPLIES Annex 5 Confidentiality commitment Annex 6 Quantity of the Articles (restricted, TL IV) Please note that the numbering of the annexes differs between the Contract draft and the Call for tenders. The numbering of the Annexes to the Contract draft is based on the order of precedence applied in the Contract., LOT 1: Electrolytes (ringer's solution) 1000 ml (intravenous infusion, ATC B05BB01) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Electrolytes (ringer's solution) 1000 ml (intravenous infusion, ATC B05BB01) - Active pharmaceutical ingredient: Electrolytes (ringer's solution) - Container size: 1000 ml - Pharmaceutical form: intravenous infusion - ATC code: B05BB01 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 2: Electrolytes with carbohydrates 50 mg/ml (500 ml, solution for infusion, ATC B05BB02) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Electrolytes with carbohydrates 50 mg/ml (500 ml, solution for infusion, ATC B05BB02) - Active pharmaceutical ingredient: Electrolytes with carbohydrates - Strength: 50 mg/ml - Container size: 500 ml - Pharmaceutical form: solution for infusion - ATC code: B05BB02 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 3: Esketamine 25 mg/ml (2 ml, solution for injection/infusion, ATC N01AX14) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Esketamine 25 mg/ml (2 ml, solution for injection/infusion, ATC N01AX14) - Active pharmaceutical ingredient: Esketamine - Strength: 25 mg/ml - Container size: 2 ml - Pharmaceutical form: solution for injection/infusion, vial/ampoule - ATC code: N01AX14 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 4: Oxycodone 10 mg/ml (1 ml, solution for injection, ATC N02AA05) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Oxycodone 10 mg/ml (1 ml, solution for injection, ATC N02AA05) - Active pharmaceutical ingredient: Oxycodone - Strength: 10 mg/ml - Container size: 1 ml - Pharmaceutical form: solution for injection, vial/ampoule - ATC code: N02AA05 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 5: Oxycodone 10 mg/ml (10 ml, solution for injection, ATC N02AA05) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Oxycodone 10 mg/ml (10 ml, solution for injection, ATC N02AA05) - Active pharmaceutical ingredient: Oxycodone - Strength: 10 mg/ml - Container size: 10 ml - Pharmaceutical form: solution for injection, vial/ampoule - ATC code: N02AA05 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 6: Levetiracetam 100 mg/ml (5 ml, concentrate for solution for infusion, ATC N03AX14) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Levetiracetam 100 mg/ml (5 ml, concentrate for solution for infusion, ATC N03AX14) - Active pharmaceutical ingredient: Levetiracetam - Strength: 100 mg/ml - Container size: 5 ml - Pharmaceutical form: concentrate for solution for infusion, vial - ATC code: N03AX14 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 7: Cefuroxime 1500 mg (powder for solution for injection, ATC J01DC02) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Cefuroxime 1500 mg (powder for solution for injection, ATC J01DC02) - Active pharmaceutical ingredient: Cefuroxime - Strength: 1500 mg - Pharmaceutical form: powder for solution for injection, vial - ATC code: J01DC02 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 8: Vancomycin 1000 mg (powder for solution for injection, ATC J01XA01) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Vancomycin 1000 mg (powder for solution for injection, ATC J01XA01) - Active pharmaceutical ingredient: Vancomycin - Strength: 1000 mg - Pharmaceutical form: powder for solution for injection, vial - ATC code: J01XA01 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 9: Enoxaparin 100 mg/ml (1 ml, sub-cutaneous, ATC B01AB05) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Enoxaparin 100 mg/ml (1 ml, sub-cutaneous, ATC B01AB05) - Active pharmaceutical ingredient: Enoxaparin - Strength: 100 mg/ml - Container size: 1 ml - Pharmaceutical form: sub-cutaneous, pre-filled syringe - ATC code: B01AB05 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU)., LOT 10: Tranexamic acid 100 mg/ml (10 ml, intra muscular/intravenous, ATC B02AA02) The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Tranexamic acid 100 mg/ml (10 ml, intra muscular/intravenous, ATC B02AA02) - Active pharmaceutical ingredient: Tranexamic acid - Strength: 100 mg/ml - Container size: 10 ml - Pharmaceutical form: intra muscular/intravenous, vial/ampoule - ATC code: B02AA02 The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the Article is described in Annex 1. Quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 6, the Customer shall be entitled to purchase 100 % extra to the original quantities described in the Annex 6 (later referred as "Option"). The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Stock Keeping Unit (SKU).,